financetom
Business
financetom
/
Business
/
Amazon beats Q3 net sales, EPS estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Amazon beats Q3 net sales, EPS estimates
Oct 30, 2025 1:32 PM

Overview

* Amazon Q3 2025 net sales grow 13% yr/yr, beating analysts' expectations, driven by AWS and international segments

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company's operating income impacted by special charges, net income rises significantly

Outlook

* Amazon expects Q4 2025 net sales between $206.0 bln and $213.0 bln

* Company anticipates Q4 2025 operating income between $21.0 bln and $26.0 bln

* Amazon's ( AMZN ) guidance includes a favorable FX impact of 190 basis points

Result Drivers

* AWS GROWTH - AWS sales increased 20% yr/yr, driven by strong demand for AI and core infrastructure, according to CEO Andy Jassy

* INTERNATIONAL SALES - International segment sales rose 14% yr/yr, aided by favorable foreign exchange rates

* SPECIAL CHARGES - Operating income impacted by $2.5 bln legal settlement and $1.8 bln severance costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Beat $180.17 $177.75

Sales bln bln (53

Analysts

)

Q3 EPS Beat $1.95 $1.57

(49

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 71 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the department stores peer group is "buy"

* Wall Street's median 12-month price target for Amazon.com Inc ( AMZN ) is $265.00, about 13.1% above its October 29 closing price of $230.30

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vermilion Closes US$400 Million Senior Unsecured Notes Offering
Vermilion Closes US$400 Million Senior Unsecured Notes Offering
Feb 11, 2025
11:17 AM EST, 02/11/2025 (MT Newswires) -- Vermilion Energy ( VET ) on Tuesday said it closed its US$400 million private offering of eight-year senior unsecured notes. The notes mature on Feb. 15, 2033 and have a fixed coupon of 7.250% per annum. The company's shares were last seen up $0.39 to $13.97 on the Toronto Stock Exchange. Price: 13.96,...
Sunoco Q4 Results Show Margin Pressure In Fuel Distribution, Misses Estimates
Sunoco Q4 Results Show Margin Pressure In Fuel Distribution, Misses Estimates
Feb 11, 2025
Sunoco LP ( SUN ) shares are trading lower after it reported fourth-quarter revenues of $5.27 billion, which missed the consensus of $6.21 billion. Adjusted distributable cash flow of $261 million was higher than $148 million a year ago. Adjusted EBITDA increased to $439 million from $236 million a year ago. EPS of $0.75 missed the consensus of $1.34. The Fuel Distribution segment sold around 2.2 billion gallons of fuel (broadly flat year over year), with the fuel margin for all gallons sold...
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
Feb 11, 2025
On Tuesday, Novartis AG ( NVS ) agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company. Anthos is developing abelacimab, a late-stage medicine to prevent stroke and systemic embolism in patients with atrial fibrillation, a type of irregular heartbeat, or arrhythmia, that occurs when the upper chambers of the heart beat irregularly. Novartis ( NVS )...
--Starbucks Seeks Dismissal of Patent Owner's Defamation Suit
--Starbucks Seeks Dismissal of Patent Owner's Defamation Suit
Feb 11, 2025
11:16 AM EST, 02/11/2025 (MT Newswires) -- Price: 111.99, Change: +0.54, Percent Change: +0.48 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved